Clin Psychopharmacol Neurosci.  2021 May;19(2):262-268. 10.9758/cpn.2021.19.2.262.

miR-132 and miR-942 Expression Levels in Children with Attention Deficit and Hyperactivity Disorder: A Controlled Study

Affiliations
  • 1Department of Child and Adolescent Psychiatry, Private Clinic, Adana, Turkey
  • 2Department of Child and Adolescent Psychiatry, Gaziantep University Medical School, Gaziantep, Turkey
  • 3Department of Medical Biology, Gaziantep University Medical School, Gaziantep, Turkey

Abstract


Objective
Although attention deficit hyperactivity disorder (ADHD) is a disease with high genetic transition, our knowledge about the mechanism of the disease is limited. In this study, it was aimed to evaluate the levels of miR-132-3p and miR-942-5p that are associated with the dopamine carrier protein gene (DAT1) and dopamine receptor 5 (DRD5) genes, which have been shown to play a role in the development of ADHD.
Methods
According to the Diagnostic and Statistical Manual of Mental Disorders 5th edition, 50 children diagnosed with ADHD and 48 healthy controls were included in the study. Affective Disorders and Schizophrenia Interview Schedule-Now and Lifetime Version-Turkish Adaptation was used to evaluate ADHD and the diagnoses accompanying ADHD. Quantitative Real-Time Polymerase Chain Reaction was used to evaluate miR-132-3p and miR-942-5p expression levels.
Results
It was observed that miR-132-3p level (p = 0.001) was significantly higher with children with ADHD compared to the control group, and the level of miR-942-5p (p = 0.181) was higher in ADHD but did not reach statistically significant level.
Conclusion
In our study, we found that the increase in the miR-132-3p levels of children with ADHD may be a therapeutic target of the disease.

Keyword

Attention deficit hyperactivity disorder; MicroRNA; MiR-132-3p; MiR-942-5p
Full Text Links
  • CPN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr